Have Changes in Systemic Treatment Improved Survival in Patients with Breast Cancer Metastatic to the Brain? by Nieder, Carsten et al.
Hindawi Publishing Corporation
Journal of Oncology
Volume 2008, Article ID 417137, 5 pages
doi:10.1155/2008/417137
Research Article
Have Changes in Systemic Treatment Improved Survival in
Patients with Breast Cancer Metastatic to the Brain?
Carsten Nieder,1, 2 Kirsten Marienhagen,3 Astrid Dalhaug,1 and Jan Norum2, 3
1 Radiation Oncology Unit, Medical Department - Oncology, Nordlandssykehuset HF, 8092 Bodø, Norway
2 Institute of Clinical Medicine, Faculty of Medicine, University of Tromsø, 9037 Tromsø, Norway
3 Department of Oncology, University Hospital of North Norway, 9038 Tromsø, Norway
Correspondence should be addressed to Carsten Nieder, carsten.nieder@nlsh.no
Received 19 May 2008; Revised 2 July 2008; Accepted 16 July 2008
Recommended by Minesh Mehta
Newly developed systemic treatment regimens might lead to improved survival also in the subgroup of breast cancer patients
that harbour brain metastases. In order to examine this hypothesis, a matched pairs analysis was performed that involved one
group of patients, which were treated after these new drugs were introduced, and one group of patients, which were treated
approximately 10 years earlier. The two groups were well balanced for the known prognostic factors age, KPS, extracranial disease
status, and recursive partitioning analysis class, as well as for the extent of brain treatment. The results show that the use of systemic
chemotherapy has increased over time, both before and after the diagnosis of brain metastases. However, such treatment was
performed nearly exclusively in those patients with brain metastases that belonged to the prognostically more favourable groups.
Survival after whole-brain radiotherapy has remained unchanged in patients without further active treatment. It has improved in
prognostically better patients and especially patients that received active treatment, where the 1-year survival rates have almost
doubled. As these patient groups were small, confirmation of the results in other series should be attempted. Nevertheless, the
present results are compatible with the hypothesis that improved systemic therapy might contribute to prolonged survival in
patients with brain metastases from breast cancer.
Copyright © 2008 Carsten Nieder et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. Introduction
Whole brain radiotherapy (WBRT) continues to represent an
important palliative treatment option for patients with brain
metastases from breast cancer. Median overall survival typi-
cally is limited to 4–6 months [1]. However, many patients
have active extracranial disease and eventually die from
extracranial cancer progression. Within the last decade, sev-
eral important new treatment options for metastatic breast
cancer became available, for example, trastuzumab, taxane-
based chemotherapy, capecitabine, and more effective aro-
matase inhibitors. Therefore, the possibility exists that more
effective systemic treatment might lead to improved survival
also in the subgroup of patients harbouring brain metastases.
In order to examine this hypothesis, a matched pairs analysis
was performed that involved one group of patients, which
were treated after these new drugs were introduced, and one
group of patients, which were treated approximately 10 years
earlier.
2. Patients and Methods
The contemporary group included all patients with brain
metastases from breast cancer, which received WBRT with
10 fractions of 3 Gy between 2000 and 2007 at the University
Hospital of North-Norway. The patients (n = 32) were
identified from the database of the Radiation Oncology
facility. No patients with carcinomatous meningitis were
included. Positron emission tomography for staging was
not available. A historical control group treated with the
same WBRT regimen between 1987 and 1997 was generated.
From this larger group (n = 47), patients were selected
for a matched pairs analysis without survival information
available at the time of matching. To obtain two groups with
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Table 1: Patient characteristics.
Contemporary group, n = 32 Historical group, n = 32 P-value
Median age, range 55 yrs., 34–81 53 yrs., 29–72 >.1
Median KPS, range 70%, 50–90 70%, 30–90 >.1
Median time interval∗ 52 mo., 3–216 34 mo., 7–118 <.05
% single brain metastasis 16 34 <.05
% with MRI scan of the brain 44 41 >.1
% uncontrolled primary 3 0 >.1
% without extracranial metastases 9 9 >.1
% RPA class I versus II versus III 6 : 59 : 34 6 : 56 : 38 >.1
% GPA group I versus II versus III versus IV 0 : 0 : 62 : 38 0 : 6 : 56 : 38 >.1
Median GPA score 1.5 1.5 >.1
% chemotherapy before brain metastases diagnosis 81 69 < .1
% T1/2 N0 versus T3/4 N0 versus N+ 25 : 6 : 69 19 : 6 : 75 >.1
% with HR positive tumour 42 not available
% with HER-2 positive tumour 69 not available
KPS: Karnofsky performance status, ∗from breast cancer diagnosis to brain metastases, MRI: magnetic resonance imaging, RPA: recursive partitioning
analysis, GPA: graded prognostic assessment (Sperduto et al. [2]: 0-1 point (most unfavourable) defined as group IV, 1.5–2.5 points defined as group III,
3 points defined as group II, 3.5–4 points defined as group I), HR: hormone receptor.
comparable baseline characteristics, two matching criteria
were used: prognostic class according to the published
recursive partitioning analysis (RPA class) [3, 4] and the use
of additional local treatment for relapses after WBRT, for
example, radiosurgery (RS) or surgical resection. Informa-
tion on primary tumour features, such as hormone receptor
status and HER2 receptor status, was not available in the
historical group. Information on lymphopenia [5, 6] was
not available at all. We used the Kaplan-Meier method to
generate actuarial survival curves. These were compared
with the log rank test. Wilcoxon- and Kruskal-Wallis tests
were used to compare the baseline characteristics between
the two groups. A P-value <.05 was considered statistically
significant.
3. Results
Table 1 shows the patient characteristics for the contempo-
rary group and the matched group of 32 historical patients.
As can be seen, the groups were balanced for the established
prognostic factors. More patients in the contemporary
group had received chemotherapy before diagnosis of brain
metastases. Time to development of brain metastases was
significantly longer. The fact that more patients in the
historical group were recorded to have had single brain
metastases apparently was not related to increased use of
magnetic resonance imaging in recent years.
The majority of patients in the contemporary group
were lymph node positive, hormone receptor negative, and
HER-2 positive. Neither hormone receptor status nor HER-
2 status was statistically significant prognostic factor in this
group (P > .3). Only 4 patients had not received systemic
treatment, 2 had received endocrine treatment only, and
26 had received chemotherapy before development of brain
metastases (5 patients had 3 different lines of chemotherapy).
Twelve patients remained without systemic treatment after
WBRT, 5 received endocrine treatment only, 11 one line
of chemotherapy, and 4 at least 2 lines of chemotherapy.
Three patients received trastuzumab-containing treatment
after WBRT. As this was a matching criterion, 3 patients in
each group received RS or surgical resection for progressive
brain metastases. As a striking difference, only 8 patients
in the historical group received additional chemotherapy
after WBRT (endocrine treatment unfortunately was not
recorded).
In the contemporary group, 60% of the patients achieved
at least a partial remission of their brain metastases based
on imaging after WBRT (reduction in largest diameter of
each lesion by at least 50% without development of new
lesions). At 6 months after WBRT, 59% of the patients were
progression-free in the central nervous system. These data
are not available for the historical group. Median survival
from first diagnosis of breast cancer was 102 months in
contemporary patients with initial T1/2 N0 disease and
47.5 months in patients with more advanced disease (P <
.05). These figures are higher than in historical patients
(60.9 versus 34.7 months). Table 2 demonstrates that the
recent survival improvement from the start of WBRT
is entirely derived from RPA class II patients, while no
obvious progress was achieved in RPA class III. Analysis
of class I was not meaningful, as this group included only
2 patients. Only 2 of the contemporary patients in RPA
class III received chemotherapy after WBRT (versus one
patient in the historical group). Patients without active
treatment after WBRT had a median survival of 3.5 versus
3.2 months, that is, no improvement over time. For patients
with active treatment, median survival also remained stable
(9.0 versus 7.9 months), while the 1-year survival rate
improved from 25 to 43%. The small group (n = 6) of
patients that received the most aggressive treatment, defined
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Table 2: Survival results for the two groups.
Contemporary group, n = 32 Historical group, n = 32 P-value (log-rank test)
Median survival 5.0 mo. 3.6 mo.
1-year survival 31% 19% <.1
Median survival RPA class II 9.0 mo. 3.4 mo.
1-year survival RPA class II 42% 22% <.05
Median survival RPA class III 2.4 mo. 3.1 mo.
1-year survival RPA class III 18% 8% >.1
Table 3: Comparison with the literature, median WBRT dose 30 Gy in all studies.
Own contemporary patients Mahmoud-Ahmed et al. [7] Claude et al. [5] Bartsch et al. [8] Le Scodan et al. [6]
Treated 2000–2007 1984–2000 1991–2001 1994–2004 1998–2003
n 32 116 120 174 117
Upfront surgery/RS no no yes yes no
Median age 55 y. 50 y. 54 y. 55 y. 53 y.
Median interval 52 m. 22.5 m. 38 m. 35 m. 39 m.
Extracranial met. 91% 68% 80% unknown 94%
Previous Ctx 81% unknown 84% unknown 79%
HR positive 42% unknown 66% unknown 48%
Median survival 5.0 m. 4.2 m. 5.0 m. 7.0 m. 5.0 m.
1-year survival 31% 17% 25% 30% 28%
Median survival class II 9.0 m. 6.1 m. 9.0 m. unknown 8.0 m.
Median survival class III 2.4 m. 1.7 m. 3.0 m. unknown 3.0 m.
RS: radiosurgery, Ctx: chemotherapy, HR: hormone receptor.
as trastuzumab-containing regimens and/or brain salvage
treatment, had a median survival of 15.4 months (4 patients
survived >1 year).
4. Discussion
This matched pairs analysis was performed with two groups
of patients, which received identical local treatment for their
brain metastases and were well balanced for the known prog-
nostic factors age, KPS, extracranial disease status, graded
prognostic assessment (GPA) group, and RPA class. Unlike
the newly developed GPA, RPA class has been confirmed as
prognostic factor in patients with primary breast cancer in
several studies (Table 3). In order to obtain enough historical
patients for the matching procedure, the treatment period
was extended back to the year 1987. The recently suggested
prognostic factor lymphopenia [5, 6] has not been routinely
assessed in our department and could, therefore, not be
included. A further point that needs to be mentioned is
the lack of information on hormone receptor status, HER-
2 status, and endocrine treatment in the historical patient
group, which was treated before 1998. Thus, imbalances
regarding these parameters, which might have influenced
the survival results to some degree, cannot be ruled out. As
demonstrated in Table 4, the prognostic impact of hormone
receptor and HER-2 status is difficult to interpret at this time,
as the published studies reported inconsistent results and
are all limited in size. None of the patients in the historical
group received trastuzumab, taxanes, capecitabine, or new-
generation aromatase inhibitors.
The first interesting finding was that the interval from
initial breast cancer treatment to brain metastases has
increased by 18 months, that is, 53%. Median interval was
longer than previously reported in the literature (Table 3).
Accordingly, increased overall survival from first diagnosis
of breast cancer was evident, in particular in patients with
initial T1/2 N0 disease. Such results might be explained
by a change in the biology of the disease. However, the
numbers of patients with node-positive disease, receptor-
negative disease, and HER-2 positive disease between 2001
and 2007 argues against this explanation. Especially HER-
2 overexpression and hormone receptor negativity appear
to influence the risk of brain metastases development [16].
In fact, the data favour changes in treatment regimens as a
more likely explanation. The use of systemic chemotherapy
has increased over time, both before and after the diagnosis
of brain metastases. However, such treatment was performed
nearly exclusively in those patients with brain metastases
that belonged to the prognostically more favourable groups
(better RPA class). Whether changes in systemic treatment
are the only explanation for the marked survival improve-
ment in RPA class II in the present study is difficult to
assess. Other factors might potentially influence the results.
It is, for example, possible that more patients that previously
would have been assigned to RPA class I would now be
assigned to class II, based on better methods for detection of
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Table 4: Prognostic impact of hormone receptor and HER-2 status.
n Prognostic impact of hormone receptor status Prognostic impact of HER-2 status
Claude et al. [5] 120 none not examined
Bartsch et al. [8] 174 none none
Le Scodan et al. [6] 117 receptor negative significantly worse none
Nam et al. [9] 126 receptor negative significantly worse HER-2 negative significantly worse
Kirsch et al. [10] 95 not examined HER-2 negative significantly worse∗
Eichler et al. [11] 83 none HER-2 negative significantly worse∧
Melisko et al. [12] 112 receptor negative significantly worse none
Harputluoglu et al. [13] 144 none none
Park et al. [14] 125 none HER-2 positive significantly worse
Church et al. [15] 86 not examined HER-2 negative significantly worse∗
Own contemporary group 32 none none
∧ 80% of HER-2 overexpressing cases received trastuzumab after diagnosis of brain metastases.
∗ The difference in survival was limited to patients with HER-2 overexpressing cancer treated with trastuzumab after diagnosis of brain metastases.
extracranial metastatic disease. In addition, RPA class II is a
quite inhomogeneous group of patients with large potential
differences, for example, in extent of CNS involvement and
KPS.
In the present analysis, survival after WBRT has remained
unchanged in patients without further active treatment. It
has improved in prognostically better patients and especially
patients that received active treatment, where the 1-year
survival rates have almost doubled. As these patient groups
were small, confirmation of the results in other series should
be attempted. When looking at the literature, the series that
is best comparable to our own contemporary patients is
the one reported by Le Scodan et al. [6], which provides
almost identical survival data (Table 3). The series that
included the oldest data (back to 1984) [7], is very close
to our own historical group. Bartsch et al. confirmed that
patients without systemic treatment have significantly poorer
median survival (5 months versus 10 months in patients
with systemic treatment) [8]. These authors also found that
intensified local therapy of brain metastases improved the
outcome. Lee et al. confirmed the value of both intensified
local and systemic treatment in a series of 198 patients [17].
Other nonrandomized series suggest that RS might lead to
better local control and survival than that reported from
WBRT series [18]. The impact of chemotherapy on brain
control is less clear [19], although recent data suggest that
capecitabine might be able to induce remission of central
nervous system metastases from breast cancer [20]. Taken
together, the present results and the literature overview
are compatible with the hypothesis that improved systemic
therapy might contribute to longer survival in patients with
brain metastases from breast cancer, which qualify for active
systemic therapy in addition to upfront WBRT.
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